TransCode Therapeutics, Inc. (RNAZ )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol RNAZ
- Company TransCode Therapeutics, Inc.
- Price $8.98
- Changes Percentage 45.78
- Change 2.82
- Day Low $6.57
- Day High $12.7
- Year High $66.33
- Year Low $2.66
- Market Cap $6,196,686
- Price Avg 50 EMA (D) $6.57
- Price Avg 200 EMA (D) $18.13
- Exchange NASDAQ
- Volume 16,880,601
- Average Volume 1,172,396
- Open $6.58
- Previous Close $6.16
- EPS 5571.72
- PE 0.00
- Earnings Announcement 2025-03-28 12:00:00
- Shares Outstanding $696,249
Company brief: TRANSCODE THERAPEUTICS, INC. (RNAZ )
- Healthcare
- Biotechnology
- Mr. Thomas A. Fitzgerald M.B.A.
- https://www.transcodetherapeutics.com
- US
- N/A
- 07-08-2021
- US89357L3033
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ Corporation News
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
prnewswire.com -- BOSTON , Feb. 4, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA t...